4D Pharma logo

DDDD - 4D Pharma Share Price

99p -0.5  -0.5%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £64.8m
Enterprise Value £53.0m
Revenue £n/a
Position in Universe 1101st / 1834
Bullish
Bearish
Unlock DDDD Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DDDD Revenue Unlock DDDD Revenue

Net Income

DDDD Net Income Unlock DDDD Revenue

Normalised EPS

DDDD Normalised EPS Unlock DDDD Revenue

PE Ratio Range

DDDD PE Ratio Range Unlock DDDD Revenue

Dividend Yield Range

DDDD Dividend Yield Range Unlock DDDD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DDDD EPS Forecasts Unlock DDDD Revenue
Profile Summary

4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated January 10, 2014
Public Since February 18, 2014
No. of Shareholders: n/a
No. of Employees: 116
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 65,493,842
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DDDD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DDDD
Upcoming Events for DDDD
Friday 19th June, 2020 Estimate
4D Pharma PLC Annual Shareholders Meeting
Similar to DDDD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.